IEQ Capital’s Quince Therapeutics QNCX Stock Holding History

IEQ Capital’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,001	Closed	-$60.9K	–	2151
2026 Q1	$60.9K	Sell	3,001 -1,895	-39%	-$380K	﹤0.01%	1834
2025 Q4	$3.28M	Sell	4,896 -10	-0.2%	-$5.03K	0.01%	642
2025 Q3	$1.6M	Buy	4,906 +2,710	+123%	+$902K	﹤0.01%	840
2025 Q2	$725K	Sell	2,196 -1,838	-46%	-$420K	﹤0.01%	976
2025 Q1	$1.07M	Buy	+4,034	New	+$1.23M	0.01%	735
2024 Q2	–	Sell	-113	Closed	-$23.9K	–	1033
2024 Q1	$23.9K	Buy	+113	New	+$28.1K	﹤0.01%	962

Other funds holding QNCX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IEQ Capital's QNCX Position: Q2 2026 in Review

IEQ Capital sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 3,001 shares — an estimated $60.9K sold.

IEQ Capital first reported a position in QNCX in Q1 2024 and held it in 6 quarters. The position peaked at $3.28M in Q4 2025. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

IEQ Capital reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
IEQ Capital sold 3,001 Quince Therapeutics shares in Q2 2026, an estimated $60.9K.
IEQ Capital first reported a position in Quince Therapeutics in Q1 2024 and held it in 6 quarters.
IEQ Capital's Quince Therapeutics position peaked at $3.28M in Q4 2025.
26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.